Hess Corporation continues its quarterly dividend payments at $0.50/share, signaling strong
financial health. The bio-tech company remains a prime interest for oil investment with recent stakes by entities including
Silphium Asset Management,
Levin Capital Strategies L.P, and
Commerzbank Aktiengesellschaft FI. Several funds such as
Mission Wealth Management have significant investments in Hess, reaffirming confidence in it as a viable energy stock. Its Q4 2024 results exceeded expectations and posited strong performance. A significant development is its pending merger with
Chevron, having gained clearance from
HSR. Despite challenges, Hess displayed a robust Q4 ahead of Chevron's acquisition, with EPS and revenue surpassing forecasts. The Merger has raised concerns as the
FTC establishes conditions, notably barring
John Hess, Hess' CEO, from the board. However, share value decreased due to a delay in the sale to Chevron. Despite concerns over Chevron's dwindling reserves, Hess shareholders approved the deal while the corporation forecasts strong growth driven by
Bakken &
Guyana.
Hess Corporation HES News Analytics from Fri, 31 May 2024 07:00:00 GMT to Sat, 08 Mar 2025 06:28:30 GMT -
Rating 4
- Innovation 0
- Information 8
- Rumor 2
